CD38 and Thrombocytopenia: The main results of the pooled analyses were as follows: (1) PFS was better in patients in the anti-CD38 group; (2) OS showed a significant difference in favor of the anti-CD38 group; and (3) adverse events grade ≥ 3 such as neutropenia, thrombocytopenia, diarrhea, dyspnea, and pneumonia occurred in a significantly higher proportion of patients in the anti-CD38 group compared to the control.